No Carolina / NY / Florida
Ph: 561.316.3330

Philips Announces New Interoperability Capabilities that Offer a Comprehensive View of Patient Health for Improved Monitoring and Care Coordination

Summation

  • Interoperability between MDIP and PIC iX gives clinicians a new clinical perspective that enables the capture of streaming data flowing freely from a variety of medical device manufacturers on an open, scalable, secure platform.
  • PHIA), a global leader in health technology, has announced the interoperability of Philips Capsule Medical Device Information Platform (MDIP) with Philips Patient Information Center iX (PIC iX), providing hospitals with a first-of-its-kind, comprehensive patient overview.
  • A streamlined, standardized view of the patient can be accessed through the central station, web, or mobile application, so clinicians can act more quickly regardless of their location in the hospital.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced the interoperability of Philips Capsule Medical Device Information Platform (MDIP) with Philips Patient Information Center iX (PIC iX), providing hospitals with a first-of-its-kind, comprehensive patient overview. As a world leader monitoring more than 600 million patients each year worldwide, Philips is creating an open patient monitoring ecosystem to bring together disparate medical devices and systems on a single interface. Interoperability between MDIP and PIC iX gives clinicians a new clinical perspective that enables the capture of streaming data flowing freely from a variety of medical device manufacturers on an open, scalable, secure platform. By disseminating this information through the Patient Information Center, clinicians have a single source, comprehensive overview of a patient’s condition that helps empower caregivers to make treatment recommendations confidently from anywhere throughout the hospital’s digital environment.

Breaking down patient data barriers

Historically, data from medical device vendors has been siloed, leaving clinicians with the laborious task of referencing multiple sources to gain a complete clinical view of the patient. The inefficiencies caused by this disjointed process can impact a clinician’s ability to deliver timely diagnoses and treatments to patients. Philips is addressing technical obstacles associated with interoperability, such as device-specific connectivity protocols and security challenges across the organization, to help caregivers view, document, report, and analyze data before making care-related decisions.

Pulling data from a variety of different non-Philips devices, such as ventilators, infusion pumps, and third-party vital signs monitors, Philips presents and distributes the information in a single, standardized interface. Clinicians are then presented with a comprehensive picture of a patient’s health based on available medical device data. Access to this level of detailed information may minimize the time a clinician spends prioritizing data from multiple sources. With the goal of creating efficiencies associated with determining diagnoses and treatment decisions, this new interoperability may allow caregivers to spend more time providing direct patient care.

“Every day, clinicians make countless care decisions based on information from divided medical devices and systems. It’s time we start caring for the carers by making data more accessible,” said Christoph Pedain, General Manager, Hospital Patient Monitoring at Philips. “By ever-improving availability and accessibility of patient information, clinicians and patients benefit through enhanced workflows, insights, improved care delivery and safety measures that may lead to better health outcomes and the better use of staff and infrastructure.”

Improving clinical workflows through harmonized data

Data is captured from almost any device or patient monitor vendor with the aim of improving competencies and processes. Harmonized data is available to caregivers across the hospital. A streamlined, standardized view of the patient can be accessed through the central station, web, or mobile application, so clinicians can act more quickly regardless of their location in the hospital. Meaningful insights and status updates allow clinicians to automate administrative tasks or close information gaps, helping them save time and get back to treating patients.

“In a healthcare landscape burdened by disparate data, there exists a need to usher in the next wave of clinical innovation. But one health technology company cannot do this alone,” said Lynne A. Dunbrack, Group Vice President at International Data Corporation, a premier global provider of market intelligence. 

She added, “The only way that hospitals can achieve the next level of efficiency and quality of care is by sharing patient data across systems, vendors, and devices. With this new offering, Philips is in a unique position to help drive new vendor-to-vendor interoperability standards to better support our care providers and the patients they serve.”

Committed to an open ecosystem

This interoperability is the latest example of Philips’ journey to create a large open patient monitoring ecosystem that includes third-party applications and algorithms. The unique vendor-to-vendor interoperability helps to improve access and availability to critical patient information, supporting care delivery and collaboration. A comprehensive ecosystem allows hospitals to better leverage digital health investments and manage devices across multiple vendors. Health systems can establish a balance between standardized and personalized care across acuities and disease pathways.

Enabled by the Philips PIC iX infrastructure and applications that are centrally managed, maintained, serviced, and secured, customers will receive support and consultative services to help them navigate installation, analytics, and optimization.  More here.

More News

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Unleashing Biotech Potential: ATLATL Scientific & Miltenyi Biotec Partnership

Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy